Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
An Open Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B Cell Malignancies (CLOVER 1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER WaM)
NCT Number:
NCT02952508
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that have received at least two prior lines of therapy.
Study Documents
(MUSC NetID required for document access)